5,944 Shares in Encompass Health Corporation $EHC Purchased by Landscape Capital Management L.L.C.

Landscape Capital Management L.L.C. bought a new stake in shares of Encompass Health Corporation (NYSE:EHC) during the second quarter, Holdings Channel reports. The fund bought 5,944 shares of the company’s stock, valued at approximately $601,000.

Several other large investors have also modified their holdings of EHC. BlackRock Inc. purchased a new stake in shares of Encompass Health in the 2nd quarter worth approximately $1,059,762,000. Northwestern Mutual Wealth Management Co. raised its stake in Encompass Health by 3,059,159.7% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 3,793,482 shares of the company’s stock worth $402,640,000 after buying an additional 3,793,358 shares in the last quarter. Norges Bank purchased a new stake in Encompass Health during the fourth quarter worth $133,221,000. Price T Rowe Associates Inc. MD lifted its holdings in Encompass Health by 24.6% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 4,805,413 shares of the company’s stock worth $510,047,000 after buying an additional 948,202 shares during the period. Finally, Bank of New York Mellon Corp bought a new stake in Encompass Health during the 2nd quarter valued at $81,676,000. Institutional investors own 97.25% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on EHC shares. Leerink Partners set a $152.00 price target on Encompass Health in a research report on Friday, May 22nd. Barclays raised their price objective on Encompass Health from $140.00 to $144.00 and gave the company an “overweight” rating in a research report on Thursday, August 6th. Weiss Ratings upgraded Encompass Health from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, August 12th. TD Cowen boosted their target price on shares of Encompass Health from $125.00 to $140.00 and gave the stock a “buy” rating in a report on Monday, August 10th. Finally, UBS Group raised their price target on shares of Encompass Health from $150.00 to $155.00 and gave the company a “buy” rating in a report on Friday, August 7th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $148.71.

Insider Activity

In other news, CEO Mark J. Tarr sold 173,148 shares of the business’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $125.47, for a total transaction of $21,724,879.56. Following the sale, the chief executive officer owned 267,814 shares in the company, valued at approximately $33,602,622.58. The trade was a 39.27% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP John Patrick Darby sold 8,906 shares of the company’s stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $125.95, for a total transaction of $1,121,710.70. Following the transaction, the executive vice president owned 75,041 shares in the company, valued at approximately $9,451,413.95. This trade represents a 10.61% decrease in their position. The SEC filing for this sale provides additional information. 1.80% of the stock is currently owned by company insiders.

Encompass Health Price Performance

NYSE EHC opened at $120.24 on Monday. The firm’s fifty day simple moving average is $111.01 and its two-hundred day simple moving average is $106.47. The firm has a market capitalization of $11.86 billion, a P/E ratio of 19.58, a P/E/G ratio of 2.43 and a beta of 0.72. The company has a current ratio of 1.19, a quick ratio of 1.19 and a debt-to-equity ratio of 0.76. Encompass Health Corporation has a 12-month low of $92.77 and a 12-month high of $127.99.

Encompass Health (NYSE:EHC) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $1.55 earnings per share for the quarter, topping analysts’ consensus estimates of $1.48 by $0.07. Encompass Health had a return on equity of 18.08% and a net margin of 10.01%.The firm had revenue of $1.60 billion during the quarter, compared to analysts’ expectations of $1.57 billion. During the same quarter last year, the firm earned $1.40 EPS. The business’s quarterly revenue was up 9.6% on a year-over-year basis. Encompass Health has set its FY 2026 guidance at 6.020-6.250 EPS. Analysts forecast that Encompass Health Corporation will post 6.09 EPS for the current fiscal year.

Encompass Health Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Thursday, October 1st will be issued a $0.21 dividend. This is a boost from Encompass Health’s previous quarterly dividend of $0.19. This represents a $0.84 annualized dividend and a yield of 0.7%. The ex-dividend date of this dividend is Thursday, October 1st. Encompass Health’s dividend payout ratio is 12.38%.

Encompass Health Profile

Encompass Health Corporation is a leading provider of post‐acute healthcare services in the United States, operating a comprehensive network of inpatient rehabilitation hospitals and home health and hospice agencies. Its inpatient rehabilitation hospitals offer intensive therapy programs for patients recovering from conditions such as stroke, brain injury, spinal cord injury, cardiac and pulmonary disorders, and orthopedic procedures. Through its home health segment, Encompass Health delivers skilled nursing, physical therapy, occupational therapy and speech therapy to patients in the comfort of their homes, while its hospice services provide end‐of‐life care focused on symptom management and emotional support for patients and families.

Founded in 1984 as HealthSouth Corporation and rebranded as Encompass Health in 2018, the company has grown organically and through acquisitions to serve patients across more than 30 states.